1The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure [ J ]. N Engl J Med,1997, 336:525 -533.
2Bertram p, Wilhm R, et al. Eplerenone, a selective Aldosteone bicker, in patients with left ventricular dysfunction after myocardial infarction[J]. N Engl J Med, 2003, 348:1309 -1321.
3Cosin J, Diez J, et al. Torasemide in chronic heart failure: results of the TORIC study[J]. Eur J Heart Fail, 2002, 4:507 -513.
4rLopez B, Querejeta R, et al. Effect of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure[J]. J Am Coil Cardiol, 2004, 43: 2028 - 2035.
5Hunt SA, Baker DW, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult. Executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [ J ]. Circulation,2001,104:2996 - 3007.
6Remme WJ, Swedberg K, et al. Guidelines for the diagnosis and treatment of chronic heart failure. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology[J]. Eur Heart J, 2001,22:1527 - 1560.
7Pitt B, Poole-Wilson PA, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study [ J ]. Lancet,2000, 355:1582 - 1587.
8Cohn JN, Tognoni G, et al. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure Trial [ J ]. N Engl J Med, 2001, 345:1667 - 1675.
9Pffeffer MA, Swedberg K, et al. Effect of candesartan on morality and morbidity in patients with chronic heart failure: The CHARM-Overall programme [ J ]. Lancet, 2003, 362:759 - 766.
10CIBIS-Ⅱ Investigation and Committee. The cardiac insufficiency Bisoprolol Study Ⅱ( CIBIS- Ⅱ) : a randomised trial [J]. Lancet,1999, 353:9-13.
